Abhimanyu Gowda

PhD student @UniofOxford | Dir. @NucleateUK | Prev: @Cambridge_uni, Founder @cubiotechsoc, Fellow @join_polaris @NPLB_org

[Laura Ryan @Lyan82]

New from @instituteGC: a proposal for Lovelace Disruptive Invention Labs

Is a better science possible, & how can we build it? 🏗️

Britain should pioneer a complementary model for research at the intersection of science & engineering – inverting core assumptions of modern public R&D

[Felix A. Radtke @FARadtke]

🧵Just out in Blood @BloodPortfolio: Rapid clonal selection within early hematopoietic cell compartments presages outcome to ivosidenib combination therapy
https://t.co/aT9L5oSpKj

We study how resistance and durable remission emerge in IDH1-mutant AML.

[Verena Körber @VeKoerber]

Our paper on detecting and quantifying clonal selection from a single bulk sequencing sample is out! This was a great collaboration with @pvyas_oxford, Thomas Höfer, @asger_jakobsen and @NaserAnsariPour. Read the full story here: https://t.co/bpA30Lyy9Q

[Abhimanyu Gowda @Gowda_24]

@HannahItell @NatureMicrobiol @fredhutch @MCBSeattle Great work and interesting implications. I may have missed it but do we know how/when/if SLC35A2 (or indeed any other gene maintaining full-length glycosylation) is lost during course of disease, eventually allowing X4/dual-tropism?

[Nils_Wellhausen @wellhausrn]

Therapy resistance is a major barrier to curing cancer. However, what if we could leverage cancer resistance mechanisms to strategically install them into cell therapies, enhancing their efficacy, safety, and accessibility?
https://t.co/LKDQZPUptb

[No Patient Left Behind @NPLB_org]

It's just not right... why does insurance charge people out-of-pocket for a medicine no one would take if they didn't have to?

We need to cap these costs for patients and #fixinsurance.

Please share and help, @MariahCarey , @jessicaalba, @Eminem, @Pink, @JeromeBettis36!

[MRC MHU @MRC_MHU]

NEW SPINOUT: Yellowstone Biosciences has launched to pioneer new cancer treatments using advanced T-cell therapies based on research from co-founder & MRC MHU Deputy Director @pvyas_oxford (@vyas_lab)

Find out more: https://t.co/o1TyIMb635

[Latest News from Business Wire @NewsFromBW]

Yellowstone Biosciences launches with £16.5 million to pioneer soluble bispecific TCR-based therapies for cancer https://t.co/iSVsepip1L

[Abhimanyu Gowda @Gowda_24]

@sam_carling_ Great news! Congrats Sam

[Ugur Uslu @UgiUslu]

Check out our latest paper, published @NatureComms. We show that STING activation induces IL18 secretion and thereby enhances CAR T function. Great collaboration between @CarlHJune lab and James Chen @UTSWMedCenter.
@PennMedicine @PennMDForum @PennPPA
https://t.co/zkWtZxdoRw

[Nucleate @NucleateHQ]

Announcing the Nucleate Venture Fellowship + $4M in Nucleate Funding Prizes, together with @pillar_vc and @blueyard. APPLY by Jan 1st -https://t.co/3tYssrGRZH

Checkout our press release on Medium here for more information! https://t.co/fpueLP9JWH

[Immunology Podcast @ImmunoPodcast]

How can #BaseEditing improve #CART for blood cancers?

Drs. @CarlHJune, Saar Gill, & a team at @PennMedicine developed epitope-edited CD45 CAR T cells that were effective against several hematologic malignancies. 🩸

@ScienceTM: https://t.co/pZagDmL2fh
▶️: https://t.co/Yi0B2Xtx5h

[Asger Jakobsen @asger_jakobsen]

How do DNMT3A and TET2 mutant clones impact human haematopoiesis?

Excited to share our new pre-print where we identify the cell-intrinsic and extrinsic consequences of mutations in humans with clonal haematopoiesis:
https://t.co/V3H7q0TRpj

@pvyas_oxford @SvenTurkalj @MRC_WIMM

[Nucleate UK @NucleateUK]

Attend our upcoming exclusive event: DEMO DAY! Apply here to mix with great minds that represent the new age of biotech along with our curated network of mentors, industry experts, and investors. https://t.co/xdj8acjmEA #biotech #startup #innovation

[Sven Turkalj, PhD @SvenTurkalj]

Excited to see our latest review published today in @Hemasphere_EHA! If you are interested in the latest developments in the field of targeted therapies for Acute Myeloid Leukemia, check it out! Thanks so much to @FARadtke @pvyas_oxford @vyas_lab
https://t.co/nRHDTdbHZh

[Madelynn Whittaker @mn_whittaker]

Today in @biorxivpreprint, we describe the varied durability of epigenetic editing in the context of cardiovascular disease target genes (hPCSK9, hANGPTL3, and hAGT). https://t.co/jahfisaQoA

[paresh vyas @pvyas_oxford]

Delighted to share our new approach for high fidelity sc genotyping combined with scATAC - called GTAC! Do check it out! We love it. Great collaboration with the Hughes and Davies labs also in the WIMM. Credit to Sven, Asger, Angus and all co-authors.

https://t.co/E1k25E6kOM

[Tom Gaborski @TomGaborski]

My annual reminder that NIH and NSF still prevent international students from applying for doctoral and postdoctoral fellowships. I'm glad you're here and I know you've sacrificed a lot to be here. We're proud of you!

[Majzner_Lab @Majzner_Lab]

Happy to share the newest paper from our lab. Led by technician extraordinaire Aidan Tousley (soon to be an MD/PHD student!), this manuscript details our attempts to reimagine the structure of CARs to improve their specificity and efficacy. https://t.co/EKzcX4JaFP

[Nathan Benaich @nathanbenaich]

This really is an utterly nonsensical move that is a net negative for the UK and it’s Science Superpower ambition.

https://t.co/tqsUVESpzY